Salutaris Medical Devices

Company profile

Salutaris Medical Devices company profile

SMD is a clinical-stage radiotherapeutic company that has developed the BetaCurve™. This 510k-cleared device can deliver the optimal dose of strontium-90 beta rays to treat challenging disease activity at the back of the eye. SMD's BetaCurve™ has the potential to treat millions of people who suffer from: Advanced Macular Degeneration (wet-AMD) Chronic Central Serous Chorioretinopathy (CCSR) Choroidal Hemangiomas Early Small Ocular Melanoma Choroidal Dysplastic Nevi Wet-AMD is the leading cause of blindness amongst seniors worldwide. The current treatment (when available) is frequent lifetime eye injections directly into the eyeball. This therapy is expensive, unpleasant, and fails to deliver adequate results for many patients. Currently, SMD is focused 100% on treating the wet-AMD subtype that does not respond well to current injection therapy: PCV (polypoidal choroidal vasculopathy). Recently, the FDA cleared SMD to conduct a pivotal study for PCV. By becoming the first FDA-approved treatment for the PCV indication, we believe that SMD's radiotherapy will have a clear pathway to enter the $15 billion injection market (anti-VEGF monotherapy).